Multiple Myeloma News

News

Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM

03/05/2024

Jordan Kadish

According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...

According to a phase 3 trial,...

03/05/2024

Oncology

News

Progression-Free Survival Benefits of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone For Multiple Myeloma

01/31/2024

By Emry Lloyd

Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.

Daratumumab, bortezomib,...

01/31/2024

Journal of Clinical Pathways

News

Efficacy in Clinical Trials vs Effectiveness in the Real World for Multiple Myeloma Treatment Regimens

01/18/2024

Grace Taylor

A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.

A study by Kelvin Chan, MD, PhD,...

01/18/2024

Journal of Clinical Pathways

News

Clonal Hematopoiesis Associated With High Risk of CVD Among Patients With MM Undergoing HCT

11/29/2023

Amber Denham

Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...

Clonal hematopoiesis of...

11/29/2023

Oncology

Conference Coverage

BME Signatures at Baseline and During Treatment Enable Risk Stratifications of Patients With Multiple Myeloma

12/12/2022

Craig Ostroff

In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.

In a presentation at the 64th...

12/12/2022

Journal of Clinical Pathways

Conference Coverage

Isatuximab + Carfilzomib and Dexamethasone in Early vs Late Relapsed Multiple Myeloma

12/12/2022

Katie Herman

Thomas Martin, MD, presented at the 64th ASH Annual Meeting and Exposition a subgroup analysis of the phase 3 IKEMA study which examined updated efficacy and safety of isatuximab + carfilzomib (K) and dexamethasone (d) vs Kd in patients with...

Thomas Martin, MD, presented at...

12/12/2022

Journal of Clinical Pathways

Conference Coverage

High-Risk Lesions: A Consistent Predictor of Ultra-High Risk Multiple Myeloma

12/11/2022

Katie Herman

Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...

Martin F Kaiser, MD, FRCP,...

12/11/2022

Journal of Clinical Pathways

Conference Coverage

Molecular Variants Associated With Resistance to a Quadruplet Treatment Combination in Newly Diagnosed Multiple Myeloma

12/11/2022

Katie Herman

At the 2022 ASH Annual Meeting, Francesco Maura, MD, and colleagues investigated the molecular variants associated with resistance to a quadruplet treatment combination in patients with newly diagnosed multiple myeloma.

At the 2022 ASH Annual Meeting,...

12/11/2022

Journal of Clinical Pathways

Conference Coverage

Racial and Ethnic Differences in Clinical Outcomes Among Patients With Multiple Myeloma Treated with CAR T Therapy

12/10/2022

Craig Ostroff

At the 64th ASH Annual Meeting and Exposition, Lauren C Peres, PhD, MPH, and colleagues explore the racial and ethnic differences in safety, efficacy, and outcomes among patients with relapsed/refractory multiple myeloma who were treated with...

At the 64th ASH Annual Meeting...

12/10/2022

Journal of Clinical Pathways

Conference Coverage

No Evidence That BCMA Expression Is Completely Lost Following Belamaf Treatment in Patients With RRMM

12/10/2022

Craig Ostroff

In a presentation at the 64th Annual ASH Meeting and Exposition, Daniel E Lowther, PhD, and colleagues discuss their study to determine if immune impairment and complete target loss were seen in patients with relapsed/refractory multiple...

In a presentation at the 64th...

12/10/2022

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Multiple Myeloma News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products